{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:20:07Z","timestamp":1792171207340,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T00:00:00Z","timestamp":1424995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T00:00:00Z","timestamp":1424995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2015.6","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T14:14:10Z","timestamp":1425046450000},"page":"e285-e285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs"],"prefix":"10.1038","volume":"5","author":[{"given":"T","family":"Narita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7859-3227","authenticated-orcid":false,"given":"K","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,27]]},"reference":[{"key":"BFbcj20156_CR1","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","volume":"100","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Intergroupe Francophone du My\u00e9lome. Blood 2002; 100: 1579\u20131583.","journal-title":"Blood"},{"key":"BFbcj20156_CR2","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","volume":"106","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837\u20132840.","journal-title":"Blood"},{"key":"BFbcj20156_CR3","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","volume":"28","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630\u20134634.","journal-title":"J Clin Oncol"},{"key":"BFbcj20156_CR4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.leu.2404669","volume":"21","author":"H Chang","year":"2007","unstructured":"Chang H, Qi Q, Xu W, Patterson B . c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. Leukemia 2007; 21: 1572\u20131574.","journal-title":"Leukemia"},{"key":"BFbcj20156_CR5","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569\u20134575.","journal-title":"Blood"},{"key":"BFbcj20156_CR6","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","volume":"117","author":"H Avet-Loiseau","year":"2011","unstructured":"Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011; 117: 2009\u20132011.","journal-title":"Blood"},{"key":"BFbcj20156_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"The International Myeloma Working Group","year":"2003","unstructured":"The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749\u2013757.","journal-title":"Br J Haematol"},{"key":"BFbcj20156_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbcj20156_CR9","first-page":"559","volume":"90","author":"E Tajima","year":"2005","unstructured":"Tajima E, Uranishi M, Iida S, Komatsu H, Nitta M, Ueda R . Global real-time quantification\/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myeloma. Haematologica 2005; 90: 559\u2013562.","journal-title":"Haematologica"},{"key":"BFbcj20156_CR10","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/j.leukres.2013.09.026","volume":"37","author":"A Inagaki","year":"2013","unstructured":"Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H et al. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leuk Res 2013; 37: 1648\u20131655.","journal-title":"Leuk Res"},{"key":"BFbcj20156_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/jcp.2007.049585","volume":"61","author":"J Yeung","year":"2008","unstructured":"Yeung J, Chang H . Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008; 61: 832\u2013836.","journal-title":"J Clin Pathol"},{"key":"BFbcj20156_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","volume":"37","author":"G An","year":"2013","unstructured":"An G, Xu Y, Shi L, Zou D, Deng S, Sui W et al. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res 2013; 37: 1251\u20131257.","journal-title":"Leuk Res"},{"key":"BFbcj20156_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc2460","volume":"8","author":"A Eych\u00e8ne","year":"2008","unstructured":"Eych\u00e8ne A, Rocques N, Pouponnot C . A new MAFia in cancer. Nat Rev Cancer. 2008; 8: 683\u2013693.","journal-title":"Nat Rev Cancer."},{"key":"BFbcj20156_CR14","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1038\/bcj.2013.67","volume":"4","author":"NI Herath","year":"2014","unstructured":"Herath NI, Rocques N, Garancher A, Eych\u00e8ne A, Pouponnot C . GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J 2014; 4: e175.","journal-title":"Blood Cancer J"},{"key":"BFbcj20156_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1021\/jm401073p","volume":"57","author":"MV Reddy","year":"2014","unstructured":"Reddy MV, Akula B, Cosenza SC, Athuluridivakar S, Mallireddigari MR, Pallela VR et al. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). J Med Chem 2014; 57: 578\u2013599.","journal-title":"J Med Chem"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj20156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20156","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:56:46Z","timestamp":1672912606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj20156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,27]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2]]}},"alternative-id":["BFbcj20156"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,27]]},"assertion":[{"value":"27 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SI received research funding from the Bristol-Myers Squibb Co., Chugai Pharmaceutical Co. Ltd., Taiho Phamaceutical Co. Ltd., Celgene K.K., Kyowa Hakko Kirin Co., Ltd., Ono Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd. Honoraria from Janssen Pharmaceutical K.K., Celgene K.K. and Ono Pharmaceutical Co. Ltd. T.H.; Honoraria from Celgene Co., Ltd. KT received Honoraria from Celgene Co., Ltd. Research funding from Taiho Phamaceutical Co. Ltd., Celgene K.K., Ono Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co. Ltd. M.R.; Research funding from Celgene Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}